Stock Price Movement and Market Context
On 19 Mar 2026, Alembic Pharmaceuticals Ltd. recorded an intraday low of Rs.659.55, representing a 2.4% drop from its previous close. The stock underperformed its sector by 0.27% and declined by 1.73% on the day. This new low contrasts sharply with its 52-week high of Rs.1,107.80, underscoring a substantial downward trend over the past year.
The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum. This technical positioning aligns with the broader market environment, where the Sensex itself opened sharply lower by 1,953.21 points before recovering modestly to trade at 74,956.20, still down 2.28% on the day. The Sensex remains 4.71% above its own 52-week low of 71,425.01 and is trading below its 50-day moving average, which is itself below the 200-day moving average, indicating a bearish market trend.
Financial Performance and Valuation Metrics
Over the last year, Alembic Pharmaceuticals Ltd. has delivered a total return of -21.13%, significantly underperforming the Sensex’s modest decline of -0.62%. The company’s long-term growth has been subdued, with operating profit shrinking at an annualised rate of -8.78% over the past five years. This contraction in profitability has been accompanied by flat results in the December 2025 half-year period.
Key financial ratios highlight some areas of concern. The inventory turnover ratio for the half-year stands at a low 2.79 times, indicating slower movement of stock compared to industry norms. The debt-equity ratio, while still moderate at 0.28 times, is the highest recorded for the company in recent periods. Quarterly earnings per share (EPS) have also declined to Rs.6.77, reflecting pressure on profitability.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Comparative Performance and Market Position
In addition to underperforming the Sensex, Alembic Pharmaceuticals has lagged behind the BSE500 index over the last three years, one year, and three months. This consistent underperformance highlights challenges in both the near and long term. The company’s Mojo Score currently stands at 37.0, with a Mojo Grade of Sell, downgraded from Hold as of 25 Nov 2025. The stock is classified as a small-cap, reflecting its market capitalisation relative to larger peers.
Despite these headwinds, Alembic Pharmaceuticals maintains a relatively strong ability to service its debt, with a low Debt to EBITDA ratio of 0.90 times. Return on Capital Employed (ROCE) is reported at 12.6%, and the enterprise value to capital employed ratio is an attractive 2.2, suggesting valuation metrics that are discounted compared to peer averages.
Profitability has shown some improvement, with profits rising by 11.7% over the past year, even as the stock price declined. The company’s Price/Earnings to Growth (PEG) ratio stands at 1.7, indicating a valuation that factors in moderate growth expectations. Institutional holdings are relatively high at 20.41%, reflecting a significant stake held by investors with substantial analytical resources.
Considering Alembic Pharmaceuticals Ltd.? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Technical Indicators and Market Sentiment
Technical analysis of Alembic Pharmaceuticals Ltd. reveals predominantly bearish signals across multiple timeframes. The Moving Average Convergence Divergence (MACD) indicator is bearish on both weekly and monthly charts. Bollinger Bands also indicate bearish trends in these periods. The daily moving averages confirm a bearish stance, with the stock trading below all key averages.
Other momentum indicators such as the Know Sure Thing (KST) and Dow Theory assessments are mildly bearish on weekly and monthly scales. The On-Balance Volume (OBV) indicator similarly reflects mild bearishness, suggesting that selling pressure has been consistent over recent weeks and months. The Relative Strength Index (RSI) does not currently signal any oversold or overbought conditions, indicating a neutral momentum in the short term.
Summary of Current Concerns
The stock’s decline to a 52-week low is underpinned by a combination of subdued long-term growth, flat recent financial results, and technical weakness. The low inventory turnover ratio and rising debt-equity ratio contribute to cautious sentiment. Underperformance relative to major indices and peers further highlights the challenges faced by Alembic Pharmaceuticals Ltd. in maintaining investor confidence and market momentum.
Valuation and Debt Servicing Strengths
Despite the recent price weakness, the company’s ability to service debt remains solid, supported by a low Debt to EBITDA ratio. Valuation metrics such as ROCE and enterprise value to capital employed suggest that the stock is trading at a discount relative to historical peer valuations. Profit growth over the past year, although not reflected in the share price, indicates some resilience in the company’s earnings profile.
Conclusion
Alembic Pharmaceuticals Ltd.’s stock reaching a 52-week low of Rs.659.55 reflects a period of subdued performance and technical weakness amid broader market pressures. While the company faces challenges in growth and profitability metrics, its debt servicing capacity and valuation ratios provide some stabilising factors. The stock’s current technical indicators remain bearish, consistent with the downward price trend observed over the past year.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
